Leinco Technologies

Anti-Human CTLA-4 (Ipilimumab) - Fc Muted™ Biotin

Product Code:
 
LEI-LT1606
Product Group:
 
Primary Antibodies
Host Type:
 
Human
Antibody Isotype:
 
Human IgG1κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
MDX-010
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
Shipping:
 
2-8°C
Storage:
 
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-LT1606-100ug100 ug£377.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
CTLA4 is constitutively expressed in regulatory T cells.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Biotin
Format:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Human CTLA-4
Long Description:
Cytotoxic T-lymphocyte?associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body?s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body?s own immune response against cancer cells.?2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.
NCBI Gene:
1493
Target:
CTLA-4

References

1. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33. 2. Soo, RA. et al. (2017) Lancet Oncol. 18(12):e731-e741. 3. Lipson, EJ. and Drake, CG. (2011) Clin Cancer Res 17(22):6958-62.